



Rec'd PCT/PTO 30 DEC 2004
PCT/BE 03/00117 #2



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


REC'D 04 SEP 2003

I, the undersigned, being an officer duly authorised in accordance with ~~Section 74(1) Pat (4)~~ of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



P. Mahoney

Signed


Dated 30 June 2003

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977
(Rule 16)



03JUL02 E730398-1 D10059
P01/7700 0.00-0215293.2

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference

LRD-GB-1-415

2. Patent application number

(The Patent Office will fill in this part)

0215293.2

- 3 JUL 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Rega Foundation, Minderbroederstraat 10, 3000 Leuven

Represented by Prof. Dr. Erik De Clercq, President, Rega Foundation

Patents ADP number (if you know it)

7893529001

If the applicant is a corporate body, give the country/state of its incorporation

Belgium

4. Title of the invention

Viral Inhibitors

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

K.U. Leuven R&D

care off;

Hubert Velge

Neaves Cottage

Neaves Lane - Glyndebourne

East Sussex BN8 5UA

Patents ADP number (if you know it)

8049165002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

Yes

Patents Form 1/77

0040717:03 JUL 02 12:41

Patents Form 1/77

3. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 43

Claim(s) 10

Abstract 1

Drawing(s) 0

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 2

Request for preliminary examination and search (Patents Form 8/77) 1

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

1 fax cover sheet

1 fee sheet with request for fax back service

I/We request the grant of a patent on the basis of this application.

11.

Prof. Dr. Erik De Clercq

Signature

Date

02.07.2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Hubert Velge
+44 7940 540 397**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

DUPLICATE

Viral inhibitors

FIELD OF THE INVENTION

5 The present invention relates to a series of novel imidazo[4,5-c]pyridine derivatives, processes for their preparation, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, preferably infections with viruses belonging to the family of the Flaviviridae and more preferably infections with hepatitis-C-virus (HCV). The present invention also relates to the use of novel imidazo[4,5-c]pyridine
10 derivatives to treat viral infections and their use to manufacture a medicine to treat viral infections, preferably infections with viruses belonging to the family of the Picornaviridae and more preferably infections with Coxsackie viruses.

BACKGROUND OF THE INVENTION

15 The family of the Flaviviridae consists of 3 genera, the pestiviruses, the flaviviruses and the hepaciviruses and also contains the hepatitis G virus (HGV/GBV-C) that has not yet been assigned to a genus. Pestiviruses such as the Classical Swine Fever Virus (CSFV), the Bovine Viral Diarrhea Virus (BVDV) and the Border Disease Virus (BDV) cause infections of
20 domestic livestock (respectively pigs, cattle and sheep) and are responsible for significant economic losses worldwide. BVDV, the prototypic representative of the pestivirus genus is ubiquitous and causes a range of clinical manifestations, including abortion, teratogenesis, respiratory problems, chronic wasting disease, immune system dysfunction, and predisposition to secondary viral and bacterial infections and may also cause acute fatal
25 disease. Fetuses of cattle can be infected persistently with BVDV, these animals remain viremic throughout life and serve as a continuous sources for virus spread in herds.

Vaccines are used in some countries with varying degrees of success to control pestivirus disease. In other countries, animal culling and slaughter are used to contain pestivirus disease
30 outbreaks (Leyssen P, et al., Clin Microbiol Rev. 2000 Jan;13(1):67-82).

The World Health Organization estimates that world-wide 170 million people are chronically infected with HCV (Leyssen P, et al., Clin Microbiol Rev. 2000 Jan;13(1):67-82). These chronic carriers are at risk of developing cirrhosis and/or liver cancer. The only treatment

option available today is the use of (pegylated) interferon α -2 together with ribavirin. However, the response rate to this treatment is only partial and often transient and treatment is associated with serious adverse effects. The development of new and specific anti-HCV treatments is a high priority. The study of specific inhibitors of HCV replication has been hampered by the fact that it is not possible to propagate HCV (efficiently) in cell culture. Since HCV and pestiviruses belong to the same virus family and share many similarities (organisation of the genome, analogous gene products and replication cycle), pestiviruses have been adopted as a model and surrogate for HCV.

One compound VP32947 or (3-[[[(2-dipropylamino)ethyl]thio]-5H-1,2,4-triazino[5,6-b]indole has been reported to selectively inhibit the replication of BVDV and other pestiviruses (Baginski SG et al., Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7981-6). There is no treatment strategy available for controlling infections caused by pestiviruses.

Coxsackie viruses belong to the group of the enteroviruses, family of the Picornaviridae. They cause a heterogeneous group of infections including herpangina, aseptic meningitis, a common-cold-like syndrome, a non-paralytic poliomyelitis-like syndrome, epidemic pleurodynia (an acute, febrile, infectious disease generally occurring in epidemics), hand-foot-mouth syndrome, pediatric and adult pancreatitis and serious myocarditis.

Currently only pleconaril (3-13,5-dimethyl-4-[[3-methyl-5-isoxazolyl]propyl]phenyl]-5-(trifluoromethyl-1,2,4-oxadiazole) and enviroxime [2-amino-1-(isopropylsulfonyl)-6-benzimidazole phenyl ketone oxime] have been studied clinically for the treatment of infections with enteroviruses. Pleconaril is a so called "capsid function-inhibitor"; enviroxime prevents the formation of the RNA replicative intermediate. Enviroxime resulted in only modest clinical and virological benefit in some studies (Phillpotts RJ, Wallace J, Tyrrell DA, Tagart VB. Antimicrob Agents Chemother. 1983 May;23(5):671-5.) and no benefits in others (Miller FD, et al., Chemother. 1985 Jan;27(1):102-6.). Clinical response with pleconaril has been observed in some studies (Rotbart HA, Webster AD. Clin Infect Dis. 2001 Jan 15;32(2):228-35., Rotbart HA. Antiviral Res. 2002 Feb;53(2):83-98), but the compound has not been approved by the Food and Drug Administration (hearing of March 18th, 2002). The inhibitors of Coxsackievirus replication presented here may be used for the treatment of infections with Picornaviridae.


In view of their important pharmacological value, there is a need for drugs having selective activity against viruses belonging to the family of Flaviviridae to which also belongs the hepatitis C virus, and viruses belonging to the family of Picornaviridae.

- 5 It is the object of the present invention is to provide a novel class of compounds that are active viral inhibitors. One embodiment of present invention are inhibitors of Flaviviridae, preferably inhibitors of the pestivirus replication specifically inhibiting the replication of BVDV; closely related to hepatitis C virus (HCV) and used as a surrogate virus in drug development for HCV infection (Zitzmann N.et al., Proc. Natl. Acad. Sci. USA, 96, 11878-11882 and Bukhtiyarova,-M et al., Antivir-Chem-Chemother. 2001 Nov; 12(6): 367-73).
- 10 Another embodiment of present invention is a novel class of compounds that can be used for the treatment of infections with Picornaviridae and preferably are active inhibitors of Cocksackievirus replication.

15 ILLUSTRATIVE EMBODIMENTS OF THE INVENTION

One embodiment of present invention relates to novel substituted imidazo[4,5-c]pyridine derivatives according to the general formula (I)

20



or a pharmaceutically acceptable acid addition salt thereof and their use in a treatment of viral infection or to manufacture a medicament to treat or prevent viral infection, wherein :

25

R¹ is selected from hydrogen; phenyl substituted with 0-3 R⁶; (benzoannellated) 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R⁶; 1-naphthyl substituted with 0-3 R⁶; 2-naphthyl substituted with 0-3

R^6 ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl with the proviso that the double bond cannot be adjacent to a nitrogen.

Y is selected from the group $-(CH_2)_{0-5}$; O; S; NR^{11} ; $-CH(CH_3)-$; $-OCH_2-$; $-CH_2O-$; $-OCH_2-$
 5 CH_2- ; $-CH_2-CH_2O-$; $-CH_2-O-CH_2-$; $-SCH_2-CH_2-$; $-CH_2-CH_2S-$; $-CH_2-S-CH_2-$; $-NR^{11}-CH_2-$
 CH_2- ; $-CH_2-CH_2-NR^{11}-$; $-CH_2-NR^{11}-CH_2-$; $-C(CH_3)_2-$; (cis or trans) $-CH_2-CH=CH-$; (cis or
 trans) $-CH=CH-CH_2-$.

R^2 , R^4 and R^5 are independently selected from hydrogen; straight or branched C_{1-6} alkoxy;
 10 straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; NR^7R^8 ; OCF_3 ; CF_3 ; $C(=O)R^9$;
 phenyl; phenoxy; benzyl; hydroxymethyl.

X is selected from the group $-CH_2-$; $-CH(CH_3)-$; $-CH_2-CH_2-$; $-CH_2-CH_2-CH_2-$; $-CH_2-CH_2-$
 CH_2-CH_2 ; $-OCH_2-CH_2-$; $-SCH_2-CH_2-$; $-NR^{10}-CH_2-CH_2-$; C_{3-7} cycloalkylidene; $-C(CH_3)_2-$;
 15 $CH_2-CH(CH_3)-CH_2-$; $-CH(CH_3)-CH_2-CH_2-$; $-CH_2-CH_2-CH(CH_3)-$; $-CH=CH-CH_2-$.

R^3 is selected from phenyl substituted with 0-3 R^{17} ; (benzoannellated) 5 or 6 membered
 heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted
 with 0-2 R^{17} ; 1-naphthyl substituted with 0-3 R^{17} ; 2-naphthyl substituted with 0-3 R^{17} ; C_{3-7}
 20 cycloalkyl; C_{5-7} cycloalkenyl with the proviso that the double bond cannot be adjacent to a
 nitrogen.

R^6 and R^{17} are independently selected from the group H; straight or branched C_{1-6} alkoxy;
 straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; $NR^{13}R^{14}$; OCF_3 ; CF_3 ; $C(=O)R^{18}$;
 25 phenyl; phenoxy; benzyl; hydroxymethyl.

R^7 and R^8 are independently selected from H; straight or branched C_{1-6} alkyl; phenyl;
 $C(=O)R^{12}$.

30 alternatively, R^7 and R^8 , together with the nitrogen to which they are attached, combine to
 form a 5-6 membered ring containing 0-1 O or N atoms.

R^9 and R^{18} are independently selected from H; OH; straight or branched C_{1-6} alkyl; straight or
 branched C_{1-6} alkoxy; $NR^{15}R^{16}$; phenyl.


R^{10} and R^{11} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

5 R^{12} is selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

R^{13} and R^{14} are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

10 R^{15} and R^{16} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

A second embodiment of present invention comprises a group of compounds related to the
15 general Formula (I) wherein R^1 is directly linked to the imidazo[4,5-c]pyridine ring structure:
Formula (II):



II

or a pharmaceutically acceptable acid addition salt thereof and the use of said compounds in a
20 treatment of viral infection or to manufacture a medicament to treat viral infection, wherein:

R^1 is selected from phenyl substituted with 0-3 R^6 ; (benzoannellated) 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted
25 with 0-2 R^6 ; 1-naphthyl substituted with 0-3 R^6 ; 2-naphthyl substituted with 0-3 R^6 ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl.

R^2 , R^4 and R^5 are independently selected from hydrogen; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; NR^7R^8 ; OCF_3 ; CF_3 ; $C(=O)R^9$; phenyl; phenoxy; benzyl; hydroxymethyl.

- 5 X is selected from the group $-CH_2-$; $-CH(CH_3)-$; $-CH_2-CH_2-$; $-CH_2-CH_2-CH_2-$; $-CH_2-CH_2-CH_2-CH_2-$; $-OCH_2-CH_2-$; $-SCH_2-CH_2-$; $-NR^{10}-CH_2-CH_2-$; C_{3-7} cycloalkylidene; $-C(CH_3)_2-$; $-CH_2-CH(CH_3)-CH_2-$; $-CH(CH_3)-CH_2-CH_2-$; $-CH_2-CH_2-CH(CH_3)-$; $-CH=CH-CH_2-$.

- 10 R^3 is selected from phenyl substituted with 0-3 R^{17} ; (benzoannellated) 5 or 6 membered aromatic heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^{17} ; 1-naphthyl substituted with 0-3 R^{17} ; 2-naphthyl substituted with 0-3 R^{17} ; C_{3-7} cycloalkyl; C_{3-7} cycloalkenyl with the proviso that the double bond cannot be adjacent to a nitrogen.

- 15 R^6 and R^{17} are independently selected from the group H; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; $NR^{13}R^{14}$; OCF_3 ; CF_3 ; $C(=O)R^{18}$; phenyl; phenoxy; benzyl; hydroxymethyl.

- 20 R^7 and R^8 are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

alternatively, R^7 and R^8 , together with the nitrogen to which they are attached, combine to form a 5-6 membered ring containing 0-1 O or N atoms.

- 25 R^9 and R^{18} are independently selected from H; OH; straight or branched C_{1-6} alkyl; straight or branched C_{1-6} alkoxy; $NR^{15}R^{16}$; phenyl.


R^{10} is selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

- 30 R^{12} is selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

R^{13} and R^{14} are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

R^{15} and R^{16} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

- 5 Preferably the second embodiment of present invention comprises the group of compounds according to formula II



II

- 10 or a pharmaceutically acceptable acid addition salt thereof and the use of said compounds in a treatment of viral infection or to manufacture a medicament to treat viral infection, wherein:

R^1 is selected from phenyl substituted with 0-3 R^6 ; (benzoannellated) 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^6 ; 1-naphthyl substituted with 0-3 R^6 ; 2-naphthyl substituted with 0-3 R^6 ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl.

R^2 , R^4 and R^5 are independently selected from hydrogen; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; NR^7R^8 ; OCF_3 ; CF_3 ; $C(=O)R^9$; phenyl; phenoxy; benzyl; hydroxymethyl.

X is selected from the group $-CH_2-$; $-CH(CH_3)-$; $-CH_2-CH_2-CH_2-$; $-OCH_2-CH_2-$; $-CH=CH-CH_2-$.

25 R^3 is selected from phenyl substituted with 0-3 R^{17} ; (benzoannellated) 5 or 6 membered aromatic heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^{17} ; 1-naphthyl substituted with 0-3 R^{17} ; 2-naphthyl substituted with 0-3

R^{17} ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl with the proviso that the double bond cannot be adjacent to a nitrogen.

R^6 and R^{17} are independently selected from the group H; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; $NR^{13}R^{14}$; OCF_3 ; CF_3 ; $C(=O)R^{18}$; phenyl; phenoxy; benzyl; hydroxymethyl.

R^7 and R^8 are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

10

alternatively, R^7 and R^8 , together with the nitrogen to which they are attached, combine to form a 5-6 membered ring containing 0-1 O or N atoms.

R^9 and R^{18} are independently selected from H; OH; straight or branched C_{1-6} alkyl; straight or branched C_{1-6} alkoxy; $NR^{15}R^{16}$; phenyl.

15

R^{12} is selected from the group H; C_{1-6} straight or branched alkyl; phenyl.


R^{13} and R^{14} are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

20

R^{15} and R^{16} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

A more preferred second embodiment of present invention comprises the group of compounds according to formula II

25



or a pharmaceutically acceptable acid addition salt thereof and the use of said compound in a treatment of viral infection or to manufacture a medicament to treat viral infection, wherein:

5 R^1 is selected from phenyl substituted with 0-3 R^6 ; (benzoannellated) 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^6 ; 1-naphthyl substituted with 0-3 R^6 ; 2-naphthyl substituted with 0-3 R^6 ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl.

10 R^2 , R^4 and R^5 are hydrogen.

X is selected from the group $-\text{CH}_2-$; $-\text{CH}(\text{CH}_3)-$; $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$; $-\text{OCH}_2-\text{CH}_2-$; $-\text{CH}=\text{CH}-\text{CH}_2-$.

15 R^3 is selected from phenyl substituted with 0-3 R^{17} ; (benzoannellated) 5 or 6 membered aromatic heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^{17} ; 1-naphthyl substituted with 0-3 R^{17} ; 2-naphthyl substituted with 0-3 R^{17} ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl with the proviso that the double bond cannot be adjacent to a nitrogen.


20 R^6 and R^{17} are independently selected from the group H; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; $\text{NR}^{13}\text{R}^{14}$; OCF_3 ; CF_3 ; $\text{C}(=\text{O})\text{R}^9$; phenyl; phenoxy; benzyl; hydroxymethyl.

25 R^9 is selected from H; OH; straight or branched C_{1-6} alkyl; straight or branched C_{1-6} alkoxy; $\text{NR}^{15}\text{R}^{16}$; phenyl.

R^{13} and R^{14} are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $\text{C}(=\text{O})\text{R}^{12}$.

30 R^{15} and R^{16} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

Yet a more preferred second embodiment of present invention comprises the group of compounds according to formula II



II

5

or a pharmaceutically acceptable acid addition salt thereof and the use of said compound in a treatment of viral infection or to manufacture a medicament to treat viral infection, wherein:

10 R^1 is selected from phenyl substituted with 0-3 R^6 ; (benzoannellated) 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^6 ; 1-naphthyl substituted with 0-3 R^6 ; 2-naphthyl substituted with 0-3 R^6 .

R^2 , R^4 and R^5 are hydrogen.

15 X is selected from $-CH_2-$; $-CH(CH_3)-$; $-CH_2-CH_2-CH_2-$; $-OCH_2-CH_2-$; $-CH=CH-CH_2-$.

20 R^3 is selected from phenyl substituted with 0-3 R^{17} ; (benzoannellated) 5 or 6 membered aromatic heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^{17} ; 1-naphthyl substituted with 0-3 R^{17} ; 2-naphthyl substituted with 0-3 R^{17} .

R^6 and R^{17} are independently selected from the group H; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; $NR^{13}R^{14}$; OCF_3 ; CF_3 ; $C(=O)R^9$; phenyl; phenoxy; benzyl; hydroxymethyl.


25

R^9 is selected from H; OH; straight or branched C_{1-6} alkyl; straight or branched C_{1-6} alkoxy; $NR^{15}R^{16}$; phenyl.

R^{13} and R^{14} are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

R^{15} and R^{16} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

Most preferably the second embodiment of present invention comprises the group of compounds according to formula II



or a pharmaceutically acceptable acid addition salt thereof and the use of said compound in a treatment of viral infection or to manufacture a medicament to treat viral infection, wherein

R^1 is selected from phenyl substituted with 0-3 R^6 ; 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^6 ; 1-naphthyl substituted with 0-3 R^6 ; 2-naphthyl substituted with 0-3 R^6 .

R^2 , R^4 and R^5 are hydrogen.

X is selected from $-CH_2-$; $-CH(CH_3)-$; $-CH_2-CH_2-CH_2-$; $-OCH_2-CH_2-$; $-CH=CH-CH_2-$.

R^3 is selected from phenyl substituted with 0-3 R^{17} ; 5 or 6 membered aromatic heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^{17} ; 1-naphthyl substituted with 0-3 R^{17} ; 2-naphthyl substituted with 0-3 R^{17} .

R^6 and R^{17} are independently selected from hydrogen; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; $NR^{13}R^{14}$; OCF_3 ; CF_3 ; $C(=O)R^9$; phenyl; phenoxy; benzyl; hydroxymethyl.

- 5 R^9 is selected from H; OH; straight or branched C_{1-6} alkyl; straight or branched C_{1-6} alkoxy; $NR^{15}R^{16}$; phenyl.

R^{13} and R^{14} are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

10

R^{15} and R^{16} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

- 15 A third embodiment of present invention is a compound selected from the following group of compounds and its use in a treatment of viral infection or their use to manufacture a medicament to treat a viral infection:

- 5-(2,6-Difluorobenzyl)-2-(2,6-difluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
 20 5-Benzyl-2-(2,6-difluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
 5-(2,6-Difluorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
 5-Benzyl-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
 2-(2,6-Difluorophenyl)-5-phenethyl-5*H*-imidazo[4,5-*c*]pyridine;
 2-Phenyl-5-(3-phenyl-propyl)-5*H*-imidazo[4,5-*c*]pyridine;
 25 5-(2-Chlorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
 5-(3-Chlorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
 5-(4-Chlorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
 5-(2-Methoxybenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
 5-(3-Methoxybenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
 30 5-(4-Methoxybenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
 5-(4-Methylbenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
 5-(3-Fluorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
 5-(4-Fluorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
 5-(4-Bromobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;

- 4-(2-Phenyl-5*H*-imidazo[4,5-*c*]pyridin-5-ylmethyl)-benzonitrile;
5-(4-Trifluoromethyl-benzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Chlorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine hydrochloride;
5-(5-Chloro-2-thienylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5 5-(2-Naphthylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
2-Phenyl-5-(4-phenyl-butyl)-5*H*-imidazo[4,5-*c*]pyridine;
2-Phenyl-5-(4-phenyl-benzyl)-5*H*-imidazo[4,5-*c*]pyridine;
(*R/S*)-2-Phenyl-5-(1-phenyl-ethyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(1-Naphthylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
10 5-(2,4-Difluorobenzyl)-2-(2,6-difluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(2-chlorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(3-chlorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(4-chlorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(2-pyridyl)-5*H*-imidazo[4,5-*c*]pyridine;
15 5-(4-Bromobenzyl)-2-(2-thienyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(1-naphthyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(2-naphthyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Iodobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(3-fluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
20 5-(4-Bromobenzyl)-2-(3-methylphenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(3-bromophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(3-methoxyphenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Chlorobenzyl)-2-(3-bromophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Chlorobenzyl)-2-(3-chlorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
25 5-(2-Phenoxy-ethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(3-Phenyl-prop-2-en-1-yl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine and
5-(4-Iodobenzyl)-2-(3-bromophenyl)-5*H*-imidazo[4,5-*c*]pyridine.

DESCRIPTION OF THE INVENTION


30

GENERAL METHODS

CHEMISTRY


The compounds according to the invention are conveniently prepared in two general steps. First, a (substituted) 3,4-diaminopyridine (A) is reacted with B to give imidazo[4,5-c]pyridines C (scheme 1). If Y is COOH, then the cyclization is carried out under acidic catalysis (preferably in polyphosphoric acid at a temperature between 90 and 200 °C); other methods include reaction in 4N hydrochloric acid at reflux temperature or neat at a temperature between 90 and 180 °C (for aliphatic carboxylic acids). In the case of acid-sensitive groups like alkoxy or thiophene, the reaction can be carried out in phosphorus oxychloride at a temperature between 70 and 120 °C. Alternatively, reaction with aldehydes (Y = CHO) or their bisulfite adducts under oxidative conditions (nitrobenzene, DDQ, copper(II)acetate, O₂, sulfur etc.) gives imidazo[4,5-c]pyridines C. Other methods are the reaction of (substituted) 3,4-diaminopyridines (A) with orthoesters (Y = C(OR)₃), anhydrides (Y = OCOOR) or acid halogenides (Y = COX), etc.

Scheme 1:




The imidazo[4,5-c]pyridines C can be formulated in three tautomeric forms (1H, 3H or 5H), as shown in scheme 2.

Scheme 2:



Substituents (R^2 , R^4 and/or $R^5 \neq H$) can be introduced by two ways: i) either by cyclization of an appropriately substituted 3,4-diaminopyridine A or ii) by introduction of the substituent(s) onto the imidazo[4,5-c]pyridine C. For example, halogens can be introduced in position 7 of the imidazo[4,5-c]pyridine C by direct halogenation ($R^5 = Br$: with bromine in acetic acid or with NBS in acetic acid; $R^5 = Cl$: with chlorine in acetic acid or with NCS in acetic acid). Another example is the direct nitration ($R^5 = NO_2$), followed by reduction to give the amino group ($R^5 = NH_2$). Substituents in position 4 of the imidazo[4,5-c]pyridine C can be introduced, for example, *via* the corresponding imidazo[4,5-c]pyridine N^5 -oxides.

The second and final step is the reaction of the imidazo[4,5-c]pyridines C with an alkylating agent D ($R^6 = Cl, Br$, etc.) in an appropriate solvent (preferably DMF) under addition of a base (preferably aqueous sodium hydroxide) at ambient temperature (scheme 3).




SCHEME 3:

This reaction gives mixtures of three products (alkylation at the N^1 , N^3 or N^5 of the imidazo[4,5-c]pyridine C, respectively). For example, reaction of imidazo[4,5-c]pyridine C

($R^1 = 2,6\text{-difluorophenyl}$, $R^2 = R^4 = R^5 = H$) with 2,6-difluorobenzyl bromide gave the following mixture (scheme 4):

SCHEME 4:



5

This mixture can be separated by column chromatography (silica gel, eluent: mixture of dichloromethane and methanol). The structures of the isolated components can then be assigned by NMR spectroscopy (for example by one-dimensional NOE-techniques: irradiation at the CH_2 resonance frequency; applying this to GPRTI-8 gives signal enhancements of the protons in positions 4 and 6 of the imidazo[4,5-c]pyridine ringsystem) or by single crystal x-ray analysis.

10

Alternatively, the crude reaction mixture can be recrystallized from an appropriate solvent (mixture), e.g. from a mixture of diisopropyl ether and ethyl acetate, to give the pure N^5 alkylated products.

15

METHODOLOGY FOR DETERMINATION OF ANTIVIRAL AND CYTOSTATIC ACTIVITY

Antiviral and cytostatic activity are determined by the Methodology described below:

20

Cells and viruses: Madin-Darby Bovine Kidney (MDBK) cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with BVDV-free 5% fetal calf serum (DMEM-FCS) at 37°C in a humidified, 5% CO_2 atmosphere. BVDV-1 (strain PE515) was used to assess the antiviral activity in MDBK cells. Vero cells were maintained in the same way as MDBK cells. Vero cells were infected with Coxsackie B3 virus (strain Nancy).

25

Anti-BVDV assay: Ninety-six-well cell culture plates were seeded with MDBK cells in DMEM-FCS so that cells reached 24 hr later confluency. Then medium was removed and serial 5-fold dilutions of the test compounds were added in a total volume of 100 μ l, after which the virus inoculum (100 μ l) was added to each well. The virus inoculum used resulted in a greater than 90% destruction of the cell monolayer after 5 days incubation at 37°C. Uninfected cells and cells receiving virus without compound were included in each assay plate. After 5 days, medium was removed and 90 μ l of DMEM-FCS and 10 μ l of MTS/PMS solution (Promega) was added to each well. Following a 2 hr incubation period at 37°C the optical density of the wells was read at 498 nm in a microplate reader. The 50% effective concentration (EC₅₀) value was defined as the concentration of compound that protects 50% of the cell monolayer from virus-induced cytopathic effect.

EXAMPLES

The following examples illustrate the present invention without being limited thereto. Part A represent the preparation of the compounds whereas Part B represents the pharmacological examples.

PART A

Example 1

Preparation Of 2-(2,6-Difluorophenyl)-1(3)*H*-imidazo[4,5-*c*]pyridine

A mixture of the 3,4-diaminopyridine (2.00 g), 2,6-difluorobenzoic acid (1 equivalent) and polyphosphoric acid (50 g) was heated at 180°C for 4 h with stirring. Then the mixture was cooled to ambient temperature and poured into ice/water. The resulting mixture was neutralized by addition of solid Na₂CO₃. The crude product was collected by filtration, washed with water and dried. It was used in the next step without further purification.

Recrystallized from water; brownish crystals; mp: 189-190°C; yield: 60%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 13.20 (br s, 1H, NH), 9.04 (br s, 1H, H4), 8.37 (br d, 1H, H6, *J*=5.4 Hz), 7.76-7.61 (m, 2H, H7/4'), 7.42-7.30 (m, 2H, H3'/5').

Example 2

Preparation Of 2-Phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (GPJN-10)

5 A mixture of the 3,4-diaminopyridine (2.00 g), benzoic acid (1 equivalent) and polyphosphoric acid (50 g) was heated at 190°C for 3 h with stirring. Then the mixture was cooled to ambient temperature and poured into ice/water. The resulting mixture was neutralized by addition of solid Na₂CO₃. The crude product was collected by filtration, washed with water and dried. It was used in the next step without further purification.

10 Recrystallized from water; off-white crystals; mp: 229-230°C; yield: 96%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 8.95 (d, 1H, H₄, J=1.0 Hz), 8.31 (d, 1H, H₆, J=5.4 Hz), 8.28-8.17 (m, 2H, arom. H), 7.64-7.50 (m, 4H, arom. H).

Example 3

15

Preparation Of 5-(2,6-Difluorobenzyl)-2-(2,6-difluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine (GPRTI-8)

20 2-(2,6-Difluorophenyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.500 g) was dissolved in dry DMF (5 mL) and the resulting solution was cooled to 0°C. Aqueous 50% sodium hydroxide (1.5 equivalents) was added and the mixture was stirred for 15 min. Then 2,6-difluorobenzyl bromide (1.2 equivalents) was added portionwise and the resulting mixture was stirred for 24 h at room temperature. Finally, water (50 mL) was added, the precipitate was collected by filtration and dried to give the crude product mixture.

25

Recrystallized from ethyl acetate; colorless crystals; mp: 195-197°C; yield: 65%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.08 (br s, 1H, H₄), 8.09 (dd, 1H, H₆, J=6.6, 1.7 Hz), 7.82 (d, 1H, H₇, J=6.6 Hz), 7.63-7.46 (m, 2H, H₄/'4'), 7.29-7.13 (m, 4H, H₃/'5'/3''/5''), 5.87 (s, 2H, CH₂); MS (EI, 70 eV) *m/z* 357 (M⁺, 77%), 338 (4%), 230 (11%), 127 (100%); Anal. (C₁₉H₁₁F₄N₃) calcd.: C 63.87%, H 3.10%, N 11.76%, found: C 63.83%, H 3.15%, N 11.63%.

30

Example 4

Preparation Of 5-Benzyl-2-(2,6-difluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine (GPJN-1)

Prepared as described in example 3 from 2-(2,6-difluorophenyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.500 g) and benzyl bromide (0.444 g, 1.2 equivalents).

- 5 Recrystallized from a mixture of diisopropyl ether and ethyl acetate; off-white crystals; mp: 180-181°C (degr.); yield: 30%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.24 (br d, 1H, H4, *J*=1.5 Hz), 8.25 (dd, 1H, H6, *J*=6.9, 1.5 Hz), 7.81 (d, 1H, H7, *J*=6.9 Hz), 7.60-7.33 (m, 6H, H4'/2''/3''/4''/5''/6''), 7.26-7.13 (m, 2H, H3'/5'), 5.71 (s, 2H, CH₂).

10 Example 5

-Preparation Of 5-(2,6-Difluorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-3)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.500 g) and 2,6-difluorobenzyl bromide (0.636 g, 1.2 equivalents).

15

Recrystallized from a mixture of diisopropyl ether (25 mL) and ethyl acetate (60 mL); colorless crystals; mp: 214-216°C; yield: 64%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 8.91 (br s, 1H, H4), 8.39-8.32 (m, 2H, arom. H), 8.01 (dd, 1H, H6, *J*=6.9, 1.5 Hz), 7.72 (d, 1H, H7, *J*=6.9 Hz), 7.63-7.37 (m, 4H, arom. H), 7.30-7.16 (m, 2H, H3'/5'), 5.81 (s, 2H, CH₂).

20

Example 6

Preparation Of 5-Benzyl-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-4)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.500 g) and benzyl bromide (0.526 g, 1.2 equivalents).

25

Recrystallized from a mixture of diisopropyl ether (25 mL), ethyl acetate (50 mL) and methanol (4 mL); colorless crystals; mp: 214-216°C; yield: 33%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.09 (d, 1H, H4, *J*=1.4 Hz), 8.40-8.33 (m, 2H, arom. H), 8.18 (dd, 1H, H6, *J*=6.9, 1.4 Hz), 7.73 (d, 1H, H7, *J*=6.9 Hz), 7.52-7.32 (m, 8H, arom. H), 5.66 (s, 2H, CH₂).

30

Example 7

Preparation Of 2-(2,6-Difluorophenyl)-5-phenethyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-2)

Prepared as described in example 3 from 2-(2,6-difluorophenyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.500 g) and 2-phenylethyl bromide (0.480 g, 1.2 equivalents).

- 5 Recrystallized from a mixture of diisopropyl ether (50 mL) and ethyl acetate (40 mL); off-white crystals; mp: 184-186°C (degr.); yield: 14%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.02 (br d, 1H, H4, *J*=1.4 Hz), 8.09 (dd, 1H, H6, *J*=6.7, 1.4 Hz), 7.74 (d, 1H, H7, *J*=6.7 Hz), 7.60-7.45 (m, 1H, H4'), 7.34-7.12 (m, 7H, H3'/5'/2''/3''/4''/5''/6''), 4.74 (t, 2H, N-CH₂, *J*=7.4 Hz), 3.26 (t, 2H, CH₂, *J*=7.4 Hz).

10

Example 8

Preparation Of 2-Phenyl-5-(3-phenyl-propyl)-5*H*-imidazo[4,5-*c*]pyridine (GPJN-14)

- 15 Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 1-bromo-3-phenylpropane (0.367 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (7 mL); off-white crystals; mp: 44-46°C; yield: 44%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 8.95 (d, 1H, H4, *J*=1.4 Hz), 8.40-8.33 (m, 2H, arom. H), 8.09 (dd, 1H, H6, *J*=6.8, 1.4 Hz), 7.71 (d, 1H, H7, *J*=6.8 Hz), 7.52-7.13 (m, 8H, arom. H), 4.84 (t, 2H, N-CH₂, *J*=7.2 Hz), 2.65-2.57 (m, 2H, CH₂), 2.31-2.16 (m, 2H, CH₂).

20

Example 9

Preparation Of 5-(2-Chlorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-7)

25

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 2-chlorobenzyl chloride (0.297 g, 1.2 equivalents).

- 30 Recrystallized from a mixture of diisopropyl ether (25 mL) and ethyl acetate (65 mL); colorless crystals; mp: 224-225°C; yield: 52%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 8.99 (d, 1H, H4, *J*=1.6 Hz), 8.40-8.33 (m, 2H, arom. H), 8.10 (dd, 1H, H6, *J*=6.7, 1.6 Hz), 7.75 (d, 1H, H7, *J*=6.7 Hz), 7.59-7.34 (m, 6H, arom. H), 7.18-7.12 (m, 1H, arom. H), 5.80 (s, 2H, CH₂).

Example 10Preparation Of 5-(3-Chlorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-8)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g)
5 and 3-chlorobenzyl bromide (0.379 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (27 mL);
colorless crystals; mp: 210-212°C; yield: 54%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.12 (d, 1H,
H4, J=1.5 Hz), 8.39-8.32 (m, 2H, arom. H), 8.20 (dd, 1H, H6, J=6.7, 1.5 Hz), 7.74 (d, 1H, H7,
10 J=6.7 Hz), 7.61-7.38 (m, 7H, arom. H), 5.66 (s, 2H, CH₂).

Example 11Preparation Of 5-(4-Chlorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-9)

15 Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g)
and 4-chlorobenzyl chloride (0.297 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (24 mL);
colorless crystals; mp: 211-212°C; yield: 55%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.09 (d, 1H,
20 H4, J=1.5 Hz), 8.40-8.33 (m, 2H, arom. H), 8.17 (dd, 1H, H6, J=6.9, 1.5 Hz), 7.73 (d, 1H, H7,
J=6.9 Hz), 7.52-7.40 (m, 7H, arom. H), 5.66 (s, 2H, CH₂).

Example 12Preparation Of 5-(2-Methoxybenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-11)

25 Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g)
and 2-methoxybenzyl chloride (0.288 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (30 mL);
30 colorless crystals; mp: 182-184°C; yield: 60%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 8.94 (d, 1H,
H4, J=1.6 Hz), 8.39-8.32 (m, 2H, arom. H), 8.08 (dd, 1H, H6, J=6.7, 1.6 Hz), 7.69 (d, 1H, H7,
J=6.7 Hz), 7.51-7.29 (m, 5H, arom. H), 7.10-6.94 (m, 2H, arom. H), 5.61 (s, 2H, CH₂), 3.84
(s, 3H, OCH₃).

Example 13Preparation Of 5-(3-Methoxybenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-12)

- 5 Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 3-methoxybenzyl chloride (0.288 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (23 mL); colorless crystals; mp: 157-158°C; yield: 62%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.10 (d, 1H, H4, *J*=1.7 Hz), 8.40-8.33 (m, 2H, arom. H), 8.18 (dd, 1H, H6, *J*=6.7, 1.7 Hz), 7.72 (d, 1H, H7, *J*=6.7 Hz), 7.52-7.27 (m, 4H, arom. H), 7.10-6.89 (m, 3H, arom. H), 5.61 (s, 2H, CH₂), 3.75 (s, 3H, OCH₃).

Example 14

- 15 Preparation Of 5-(4-Methoxybenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-13)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 4-methoxybenzyl chloride (0.288 g, 1.2 equivalents).

- 20 Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (31 mL); colorless crystals; mp: 211-212°C; yield: 52%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.07 (d, 1H, H4, *J*=1.5 Hz), 8.39-8.32 (m, 2H, arom. H), 8.16 (dd, 1H, H6, *J*=6.9, 1.5 Hz), 7.70 (d, 1H, H7, *J*=6.9 Hz), 7.51-7.37 (m, 5H, arom. H), 6.99-6.92 (AA'BB', 2H, arom. H), 5.57 (s, 2H, CH₂), 3.73 (s, 3H, OCH₃).

25

Example 15Preparation Of 5-(2-Methylbenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-20)

- 30 Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 2-methylbenzyl chloride (0.259 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (44 mL); colorless crystals; mp: 223-224°C; yield: 60%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 8.93 (d, 1H,

H4, $J=1.6$ Hz), 8.41-8.33 (m, 2H, arom. H), 8.04 (dd, 1H, H6, $J=6.7, 1.6$ Hz), 7.75 (d, 1H, H7, $J=6.7$ Hz), 7.53-7.15 (m, 5H, arom. H), 6.92 (br d, 1H, arom. H, $J=7.0$ Hz), 5.73 (s, 2H, CH₂), 2.32 (s, 3H, CH₃).

5 Example 16

Preparation Of 5-(3-Methylbenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-21)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 3-methylbenzyl chloride (0.259 g, 1.2 equivalents).

10

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (15 mL); colorless crystals; mp: 183-185°C; yield: 46%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.08 (d, 1H, H4, $J=1.5$ Hz), 8.40-8.33 (m, 2H, arom. H), 8.16 (dd, 1H, H6, $J=6.7, 1.5$ Hz), 7.72 (d, 1H, H7, $J=6.7$ Hz), 7.52-7.14 (m, 7H, arom. H), 5.61 (s, 2H, CH₂), 2.29 (s, 3H, CH₃).

15

Example 17

Preparation Of 5-(4-Methylbenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-15)

20 Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 4-methylbenzyl chloride (0.259 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (32 mL); colorless crystals; mp: 206-208°C; yield: 57%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.07 (d, 1H, H4, $J=1.5$ Hz), 8.39-8.32 (m, 2H, arom. H), 8.15 (dd, 1H, H6, $J=6.7, 1.5$ Hz), 7.71 (d, 1H, H7, $J=6.7$ Hz), 7.52-7.17 (m, 7H, arom. H), 5.60 (s, 2H, CH₂), 2.28 (s, 3H, CH₃).

25

Example 18

Preparation Of 5-(2-Fluorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-17)

30 Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 2-fluorobenzyl bromide (0.349 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (37 mL); colorless crystals; mp: 209-211°C; yield: 67%; ¹H NMR (200 MHz, DMSO-d₆) δ 9.01 (br s, 1H, H4), 8.41-8.33 (m, 2H, arom. H), 8.06 (dd, 1H, H6, J=6.8, 1.6 Hz), 7.74 (d, 1H, H7, J=6.8 Hz), 7.52-7.21 (m, 7H, arom. H), 5.76 (s, 2H, CH₂).

5

Example 19

Preparation Of 5-(3-Fluorobenzyl)-2-phenyl-5H-imidazo[4,5-c]pyridine (GPJN-18)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-c]pyridine (0.300 g) and 3-fluorobenzyl bromide (0.349 g, 1.2 equivalents).

10

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (34 mL); colorless crystals; mp: 228-230°C; yield: 55%; ¹H NMR (200 MHz, DMSO-d₆) δ 9.12 (d, 1H, H4, J=1.5 Hz), 8.41-8.33 (m, 2H, arom. H), 8.20 (dd, 1H, H6, J=6.7, 1.5 Hz), 7.74 (d, 1H, H7, J=6.7 Hz), 7.52-7.15 (m, 7H, arom. H), 5.67 (s, 2H, CH₂).

15

Example 20

Preparation Of 5-(4-Fluorobenzyl)-2-phenyl-5H-imidazo[4,5-c]pyridine (GPJN-19)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-c]pyridine (0.300 g) and 4-fluorobenzyl chloride (0.267 g, 1.2 equivalents).

20

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (19 mL); colorless crystals; mp: 205-206°C; yield: 56%; ¹H NMR (200 MHz, DMSO-d₆) δ 9.11 (d, 1H, H4, J=1.7 Hz), 8.40-8.33 (m, 2H, arom. H), 8.18 (dd, 1H, H6, J=6.8, 1.7 Hz), 7.73 (d, 1H, H7, J=6.8 Hz), 7.61-7.37 (m, 5H, arom. H), 7.30-7.18 (m, 2H, arom. H), 5.64 (s, 2H, CH₂).

25

Example 21

Preparation Of 5-(4-*tert*-Butyl-benzyl)-2-phenyl-5H-imidazo[4,5-c]pyridine (GPJN-16)

30

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-c]pyridine (0.300 g) and 4-*tert*-butylbenzyl bromide (0.419 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (23 mL); colorless crystals; mp: 213-215°C; yield: 49%; ¹H NMR (200 MHz, DMSO-d₆) δ 9.07 (d, 1H, H4, J=1.6 Hz), 8.39-8.33 (m, 2H, arom. H), 8.17 (dd, 1H, H6, J=6.7, 1.6 Hz), 7.71 (d, 1H, H7, J=6.7 Hz), 7.53-7.35 (m, 7H, arom. H), 5.61 (s, 2H, CH₂), 1.24 (s, 9H, (CH₃)₃).

5

Example 22

Preparation Of 5-(4-Bromobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-22)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 4-bromobenzyl bromide (0.461 g, 1.2 equivalents).

10

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (26 mL); colorless crystals; mp: 212-214°C; yield: 45%; ¹H NMR (200 MHz, DMSO-d₆) δ 9.09 (br s, 1H, H4), 8.40-8.33 (m, 2H, arom. H), 8.17 (dd, 1H, H6, J=6.8, 1.5 Hz), 7.73 (d, 1H, H7, J=6.8 Hz), 7.64-7.58 (AA'BB', 2H, arom. H), 7.52-7.37 (m, 5H, arom. H), 5.64 (s, 2H, CH₂).

15

Example 23

Preparation Of 4-(2-Phenyl-5*H*-imidazo[4,5-*c*]pyridin-5-ylmethyl)-benzonitrile (GPJN-23)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 4-bromomethyl-benzonitrile (0.362 g, 1.2 equivalents).

20

Recrystallized twice from a mixture of diisopropyl ether (10 mL) and ethyl acetate (25 mL); pale orange crystals; mp: 93°C (degr.); yield: 34%; ¹H NMR (200 MHz, DMSO-d₆) δ 9.10 (d, 1H, H4, J=1.5 Hz), 8.40-8.33 (m, 2H, arom. H), 8.18 (dd, 1H, H6, J=6.9, 1.5 Hz), 7.91-7.85 (AA'BB', 2H, arom. H), 7.75 (d, 1H, H7, J=6.9 Hz), 7.61-7.55 (AA'BB', 2H, arom. H), 7.52-7.37 (m, 3H, arom. H), 5.77 (s, 2H, CH₂).

25

Example 24

Preparation Of 5-(4-Trifluoromethyl-benzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-24)

30

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 4-trifluoromethylbenzyl bromide (0.441 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (20 mL); colorless crystals; mp: 230-232°C; yield: 50%; ¹H NMR (200 MHz, DMSO-d₆) δ 9.12 (d, 1H, H4, J=1.6 Hz), 8.40-8.33 (m, 2H, arom. H), 8.19 (dd, 1H, H6, J=6.9, 1.6 Hz), 7.81-7.73 (m, 3H, arom. H), 7.65-7.59 (AA'BB', 2H, arom. H), 7.53-7.38 (m, 3H, arom. H), 5.78 (s, 2H, CH₂).

Example 25

Preparation Of 5-(4-Chlorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine hydrochloride (GPJN-9 x HCl)

98 mg of 5-(4-chloro-benzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-9) were dissolved in dry dichloromethane (18 mL) and to this solution was added one equivalent of HCl (1M in diethyl ether). After 2 hours the precipitate was collected by filtration and dried to give 70 % of the hydrochloride; colorless crystals; mp: 147-148°C (degr.).

Example 26

Preparation Of 5-(5-Chloro-2-thienylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-25)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 2-chloro-5-chloromethyl-thiophene (0.308 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (50 mL); off-white crystals; mp: 215-216°C; yield: 39%; ¹H NMR (200 MHz, DMSO-d₆) δ 9.07 (d, 1H, H4, J=1.5 Hz), 8.40-8.33 (m, 2H, arom. H), 8.19 (dd, 1H, H6, J=6.8, 1.5 Hz), 7.74 (d, 1H, H7, J=6.8 Hz), 7.55-7.37 (m, 3H, arom. H), 7.28 (d, 1H, thiophene-H, J=3.8 Hz), 7.08 (d, 1H, thiophene-H, J=3.8 Hz), 5.81 (s, 2H, CH₂).

Example 27

Preparation Of 5-(2-Naphthylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-26)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 2-bromomethyl-naphthalene (0.408 g, 1.2 equivalents).

Recrystallized from a mixture of ethyl acetate (20 mL) and ethanol (8 mL); colorless crystals; mp: 267°C; yield: 36%; ¹H NMR (200 MHz, DMSO-d₆) δ 9.17 (d, 1H, H4, J=1.7 Hz), 8.40-8.33 (m, 2H, arom. H), 8.23 (dd, 1H, H6, J=6.7, 1.7 Hz), 7.99-7.87 (m, 4H, arom. H), 7.74 (d, 1H, H7, J=6.7 Hz), 7.60-7.37 (m, 6H, arom. H), 5.84 (s, 2H, CH₂).

Example 28

Preparation Of 2-Phenyl-5-(4-phenyl-butyl)-5*H*-imidazo[4,5-*c*]pyridine (GPJN-27)

10 Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 1-chloro-4-phenylbutane (0.311 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (11 mL); colorless crystals; mp: 119-120°C; yield: 53%; ¹H NMR (200 MHz, DMSO-d₆) δ 8.95 (d, 1H, H4, J=1.4 Hz), 8.40-8.33 (m, 2H, arom. H), 8.07 (dd, 1H, H6, J=6.8, 1.4 Hz), 7.70 (d, 1H, H7, J=6.8 Hz), 7.52-7.37 (m, 3H, arom. H), 7.31-7.10 (m, 5H, arom. H), 4.46 (t, 2H, CH₂, J=7.1 Hz), 2.62 (t, 2H, CH₂, J=7.6 Hz), 2.00-1.85 (m, 2H, CH₂), 1.63-1.46 (m, 2H, CH₂).

Example 29

20 Preparation Of 5-(3-Methyl-but-2-enyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-28)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 4-bromo-2-methylbut-2-ene (0.275 g, 1.2 equivalents).

25 Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (11 mL); off-white crystals; mp: 162-163°C; yield: 58%; ¹H NMR (200 MHz, DMSO-d₆) δ 8.86 (d, 1H, H4, J=1.7 Hz), 8.40-8.33 (m, 2H, arom. H), 7.99 (dd, 1H, H6, J=6.8, 1.7 Hz), 7.71 (d, 1H, H7, J=6.8 Hz), 7.52-7.37 (m, 3H, arom. H), 5.57-5.47 (m, 1H, =CH), 5.06 (br d, 2H, CH₂, J=7.4 Hz), 1.86 (br s, 3H, CH₃), 1.77 (br s, 3H, CH₃).

Example 30

Preparation Of 5-Ethyl-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-29)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and ethyl iodide (0.288 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (5 mL) and ethyl acetate (12 mL); colorless crystals; mp: 188°C; yield: 22%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 8.96 (d, 1H, H4, *J*=1.6 Hz), 8.40-8.33 (m, 2H, arom. H), 8.09 (dd, 1H, H6, *J*=6.8, 1.6 Hz), 7.71 (d, 1H, H7, *J*=6.8 Hz), 7.52-7.36 (m, 3H, arom. H), 4.47 (q, 2H, CH₂, *J*=7.3 Hz), 1.52 (t, 3H, CH₃, *J*=7.3 Hz).

Example 31

Preparation Of 5-(2-(Diisopropylamino)ethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-30)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 2-(diisopropylamino)ethyl chloride hydrochloride (0.369 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (10 mL); colorless crystals; mp: 151-152°C; yield: 57%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 8.80 (d, 1H, H4, *J*=1.5 Hz), 8.39-8.33 (m, 2H, arom. H), 7.99 (dd, 1H, H6, *J*=6.8, 1.5 Hz), 7.67 (d, 1H, H7, *J*=6.8 Hz), 7.51-7.36 (m, 3H, arom. H), 4.36 (t, 2H, CH₂, *J*=5.4 Hz), 3.04-2.84 (m, 4H, 2 x CH and CH₂), 0.78 (d, 12H, 4 x CH₃, *J*=6.6 Hz).

Example 32

Preparation Of 5-(4-Pyridylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-31)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 4-chloromethyl-pyridine hydrochloride (0.303 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (15 mL); colorless crystals (hygroscopic); yield: 25%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.09 (d, 1H, H4, *J*=1.6 Hz), 8.60-8.57 (m, 2H, pyridine-H2/6), 8.40-8.33 (m, 2H, arom. H), 8.17 (dd, 1H, H6, *J*=6.8, 1.6 Hz), 7.67 (d, 1H, H7, *J*=6.8 Hz), 7.52-7.37 (m, 3H, arom. H), 7.31-7.28 (m, 2H, pyridine-H3/5), 5.74 (s, 2H, CH₂).

Example 33Preparation Of 5-(2-Pyridylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-34)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g),
5 and 2-chloromethyl-pyridine hydrochloride (0.303 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (17 mL);
colorless crystals; mp: 102-103°C; yield: 44%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.02 (d, 1H,
H4, J=1.4 Hz), 8.53 (ddd, 1H, pyridine-H6, J=4.7, 1.7, 0.8 Hz), 8.40-8.33 (m, 2H, arom. H),
10 8.13 (dd, 1H, H6, J=6.8, 1.4 Hz), 7.90-7.82 (m, 1H, pyridine-H4), 7.72 (d, 1H, H7, J=6.8 Hz),
7.52-7.33 (m, 5H, arom. H), 5.79 (s, 2H, CH₂).

Example 34Preparation Of 5-(3-Pyridylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-35)

15 Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g),
and 3-chloromethyl-pyridine hydrochloride (0.303 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (41 mL); off-
20 white crystals; mp: 53°C (degr.); yield: 46%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.14 (d, 1H,
H4, J=1.6 Hz), 8.76 (br d, 1H, pyridine-H2), 8.57 (dd, 1H, pyridine-H6, J=4.8, 1.6 Hz), 8.40-
8.33 (m, 2H, arom. H), 8.22 (dd, 1H, H6, J=6.8, 1.6 Hz), 7.90-7.84 (m, 1H, pyridine-H4),
7.74 (d, 1H, H7, J=6.8 Hz), 7.52-7.38 (m, 45H, arom. H), 5.71 (s, 2H, CH₂).

Example 35Preparation Of 2-Phenyl-5-(4-phenyl-benzyl)-5*H*-imidazo[4,5-*c*]pyridine (GPJN-32)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g)
and 4-chloromethyl-biphenyl (0.374 g, 1.2 equivalents).

30 Recrystallized from a mixture of ethyl acetate (50 mL) and ethanol (1.5 mL); colorless
crystals; mp: 247-248°C; yield: 65%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.14 (d, 1H, H4,

$J=1.4$ Hz), 8.40-8.33 (m, 2H, arom. H), 8.22 (dd, 1H, H6, $J=6.8$, 1.4 Hz), 7.75 (d, 1H, H7, $J=6.8$ Hz), 7.72-7.30 (m, 12H, arom. H), 5.71 (s, 2H, CH₂).

Example 36

5 Preparation Of (R/S)-2-Phenyl-5-(1-phenyl-ethyl)-5*H*-imidazo[4,5-*c*]pyridine (GPJN-33)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and (R/S)-1-phenylethyl bromide (0.341 g, 1.2 equivalents).

10 Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (40 mL); colorless crystals; mp: 190-192°C; yield: 57%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.13 (d, 1H, H4, $J=1.6$ Hz), 8.39-8.33 (m, 2H, arom. H), 8.19 (dd, 1H, H6, $J=6.7$, 1.6 Hz), 7.70 (d, 1H, H7, $J=6.7$ Hz), 7.53-7.31 (m, 8H, arom. H), 6.01 (q, 1H, CH, $J=7.0$ Hz), 2.04 (d, 3H, CH₃, $J=7.0$ Hz).

15

Example 37

Preparation Of 5-(1-Naphthylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-36)

Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 1-chloromethyl-naphthalene (0.326 g, 1.2 equivalents).

20

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (45 mL); colorless crystals; mp: 191°C; yield: 73%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.08 (d, 1H, H4, $J=1.5$ Hz), 8.39-8.33 (m, 2H, arom. H), 8.23-8.15 (m, 2H, arom. H), 7.75 (d, 1H, H7, $J=6.8$ Hz), 7.68-7.37 (m, 6H, arom. H), 7.25 (br d, 1H, arom. H, $J=6.6$ Hz), 6.22 (s, 2H, CH₂).

25

Example 38

Preparation Of 5-(Cyclohexylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-37)

30 Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and cyclohexylmethyl bromide (0.327 g, 1.2 equivalents) with heating at 80°C.

Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (14 mL); colorless crystals; mp: 188-189°C; yield: 36%; ¹H NMR (200 MHz, DMSO-d₆) δ 8.89 (d, 1H, H4, J=1.5 Hz), 8.39-8.33 (m, 2H, arom. H), 8.03 (dd, 1H, H6, J=6.6, 1.5 Hz), 7.69 (d, 1H, H7, J=6.6 Hz), 7.52-7.37 (m, 3H, arom. H), 4.28 (d, 2H, CH₂, J=7.4 Hz), 2.02-0.92 (m, 11H, cyclohexyl H).

Example 39

Preparation Of 5-(3-Methyl-1-butyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-38)

- 10 Prepared as described in example 3 from 2-phenyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 1-bromo-3-methylbutane (0.279 g, 1.2 equivalents).

Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (17 mL); colorless crystals; mp: 207°C; yield: 37%; ¹H NMR (200 MHz, DMSO-d₆) δ 8.96 (d, 1H, H4, J=1.5 Hz), 8.40-8.34 (m, 2H, arom. H), 8.09 (dd, 1H, H6, J=6.8, 1.5 Hz), 7.70 (d, 1H, H7, J=6.8 Hz), 7.52-7.37 (m, 3H, arom. H), 4.45 (t, 2H, CH₂, J=7.4 Hz), 1.87-1.75 (m, 2H, CH₂), 1.53 (hept, 1H, CH, J=6.6 Hz), 0.94 (d, 6H, (CH₃)₂).

Example 40

- 20 Preparation Of 5-(4-Fluorobenzyl)-2-(2,6-difluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine (GPJN-39)

Prepared as described in example 3 from 2-(2,6-difluorophenyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 4-fluorobenzyl chloride (0.225 g, 1.2 equivalents).

25 Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (10 mL); off-white crystals; mp: 104-105°C; yield: 48%; ¹H NMR (200 MHz, DMSO-d₆) δ 9.26 (d, 1H, H4, J=1.4 Hz), 8.26 (dd, 1H, H6, J=6.8, 1.4 Hz), 7.81 (d, 1H, H7, J=6.8 Hz), 7.61-7.45 (m, 3H, arom. H), 7.30-7.13 (m, 4H, arom. H), 5.69 (s, 2H, CH₂).

Example 41

Preparation Of 5-(2,4-Difluorobenzyl)-2-(2,6-difluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine (GPJN-40)

Prepared as described in example 3 from 2-(2,6-difluorophenyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.300 g) and 2,4-difluorobenzyl bromide (0.322 g, 1.2 equivalents).

- 5 Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (8 mL); off-white crystals; mp: 186-188°C; yield: 29%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.16 (br s, 1H, H4), 8.18 (dd, 1H, H6, *J*=6.8, 1.3 Hz), 7.82 (d, 1H, H7, *J*=6.8 Hz), 7.64-7.11 (m, 6H, arom. H), 5.78 (s, 2H, CH₂).

10 Example 42

Preparation Of 2-(2,6-Difluorophenyl)- 5-(2,4,6-trifluorobenzyl)-5*H*-imidazo[4,5-*c*]pyridine (GPJN-41)

- 15 Prepared as described in example 3 from 2-(2,6-difluorophenyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.200 g) and 2,4,6-trifluorobenzyl bromide (0.234 g, 1.2 equivalents).

- Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (8 mL); off-white crystals; mp: 186-187°C; yield: 26%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.06 (br s, 1H, H4), 8.08 (dd, 1H, H6, *J*=6.8, 1.6 Hz), 7.81 (d, 1H, H7, *J*=6.8 Hz), 7.61-7.46 (m, 1H, H4'),
20 7.42-7.13 (m, 4H, H3'/5'/3"/5"), 5.82 (s, 2H, CH₂).

Example 43

Preparation Of 5-(4-Bromobenzyl)-2-ethyl-5*H*-imidazo[4,5-*c*]pyridine (GPJN-48)

- 25 A mixture of the 3,4-diaminopyridine (1.00 g), propionic acid (1 equivalent) and polyphosphoric acid (25 g) was heated at 150°C for 1 h and then at 190°C for 2 h with stirring. Then the mixture was cooled to ambient temperature and poured into ice/water. The resulting mixture was made alkaline by addition of 2N NaOH and extracted with ethyl acetate (100 mL) six times. The combined organic phases were dried (Na₂SO₄) and evaporated to
30 give the crude product, which was recrystallized from ethyl acetate (100 mL) to give 56% of 2-ethyl-1(3)*H*-imidazo[4,5-*c*]pyridine as a white powder.

2-Ethyl-1(3)*H*-imidazo[4,5-*c*]pyridine (0.245 g) was dissolved in dry DMF (6 mL) and the resulting solution was cooled to 0°C. Aqueous 33% sodium hydroxide (1.5 equivalents) was

added and the mixture was stirred for 15 min. Then 4-bromobenzyl bromide (1.2 equivalents) was added portionwise and the resulting mixture was stirred for 24 h at room temperature. Finally, water (50 mL) was added, the precipitate was collected by filtration and dried to give the crude product mixture.

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (6 mL); off-white crystals; mp: 149-151°C (degr.); yield: 47%; ¹H NMR (200 MHz, DMSO-d₆) δ 8.89 (d, 1H, H4, J=1.5 Hz), 8.09 (dd, 1H, H6, J=6.8, 1.5 Hz), 7.62-7.54 (m, 3H, arom. H), 7.39-7.32 (AA'BB', 2H, arom. H), 5.60 (s, 2H, CH₂), 2.84 (q, 2H, CH₂, J=7.5 Hz), 1.30 (t, 3H, CH₃, J=7.5 Hz).

Example 44

Preparation Of 5-(4-Bromobenzyl)-2-(2-chlorophenyl)-5H-imidazo[4,5-c]pyridine (GPJN-54)

A mixture of the 3,4-diaminopyridine (1.00 g), 2-chlorobenzoic acid (1 equivalent) and polyphosphoric acid (25 g) was heated at 190°C for 3 h with stirring. Then the mixture was cooled to ambient temperature and poured into ice/water. The resulting mixture was made alkaline by addition of 2N NaOH and the resulting precipitate was collected by filtration and dried. The crude product was recrystallized from a mixture of water (100 mL) and ethanol (17 mL) to give 67% of 2-(2-chlorophenyl)-1(3)H-imidazo[4,5-c]pyridine as an off-white powder.

2-(2-Chlorophenyl)-1(3)H-imidazo[4,5-c]pyridine (0.383 g) was dissolved in dry DMF (10 mL) and the resulting solution was cooled to 0°C. Aqueous 33% sodium hydroxide (1.5 equivalents) was added and the mixture was stirred for 15 min. Then 4-bromobenzyl bromide (1.2 equivalents) was added portionwise and the resulting mixture was stirred for 24 h at room temperature. Finally, water (80 mL) was added, the precipitate was collected by filtration and dried to give the crude product.

Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (25 mL); pale orange powder; mp: 190-192°C; yield: 33%; ¹H NMR (200 MHz, DMSO-d₆) δ 9.21 (d, 1H, H4, J=1.6 Hz), 8.22 (dd, 1H, H6, J=6.8, 1.6 Hz), 8.09-8.02 (m, 1H, arom. H), 7.80 (d, 1H, H7, J=6.8 Hz), 7.65-7.51 (m, 3H, arom. H), 7.46-7.38 (m, 4H, arom. H), 5.67 (s, 2H, CH₂).

Example 45

Preparation Of 5-(4-Bromobenzyl)-2-(3-chlorophenyl)-5*H*-imidazo[4,5-*c*]pyridine (GPJN-55)

5 A mixture of the 3,4-diaminopyridine (1.00 g), 3-chlorobenzoic acid (1 equivalent) and polyphosphoric acid (25 g) was heated at 190°C for 3 h with stirring. Then the mixture was cooled to ambient temperature and poured into ice/water. The resulting mixture was made alkaline by addition of 2N NaOH and the resulting precipitate was collected by filtration and dried. The crude product was recrystallized from a mixture of water (100 mL) and ethanol (180 mL) to give 63% of 2-(3-chlorophenyl)-1(3)*H*-imidazo[4,5-*c*]pyridine as a white
10 powder.

2-(3-Chlorophenyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.383 g) was dissolved in dry DMF (10 mL) and the resulting solution was cooled to 0°C. Aqueous 33% sodium hydroxide (1.5 equivalents) was added and the mixture was stirred for 15 min. Then 4-bromobenzyl bromide
15 (1.2 equivalents) was added portionwise and the resulting mixture was stirred for 24 h at room temperature. Finally, water (80 mL) was added, the precipitate was collected by filtration and dried to give the crude product.

Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (45 mL);
20 colorless powder; mp: 155-157°C; yield: 42%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.16 (d, 1H, H4, *J*=1.5 Hz), 8.35-8.28 (m, 2H, arom. H), 8.20 (dd, 1H, H6, *J*=6.9, 1.5 Hz), 7.80 (d, 1H, H7, *J*=6.9 Hz), 7.64-7.38 (m, 6H, arom. H), 5.66 (s, 2H, CH₂).

Example 46

25 Preparation Of 5-(4-Bromobenzyl)-2-(4-chlorophenyl)-5*H*-imidazo[4,5-*c*]pyridine (GPJN-56)

A mixture of the 3,4-diaminopyridine (1.00 g), 4-chlorobenzoic acid (1 equivalent) and polyphosphoric acid (25 g) was heated at 190°C for 3 h with stirring. Then the mixture was cooled to ambient temperature and poured into ice/water. The resulting mixture was made
30 alkaline by addition of 2N NaOH and the resulting precipitate was collected by filtration and dried. The crude product was recrystallized from a mixture of water (100 mL) and ethanol (110 mL) to give 47% of 2-(4-chlorophenyl)-1(3)*H*-imidazo[4,5-*c*]pyridine as a colorless powder.

2-(4-Chlorophenyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.383 g) was dissolved in dry DMF (10 mL) and the resulting solution was cooled to 0°C. Aqueous 33% sodium hydroxide (1.5 equivalents) was added and the mixture was stirred for 15 min. Then 4-bromobenzyl bromide (1.2 equivalents) was added portionwise and the resulting mixture was stirred for 24 h at room temperature. Finally, water (80 mL) was added, the precipitate was collected by filtration and dried to give the crude product.

Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (25 mL); off-white powder; mp: 214-215°C; yield: 67%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.13 (d, 1H, H4, *J*=1.6 Hz), 8.39-8.32 (AA'BB', 2H, arom. H), 8.18 (dd, 1H, H6, *J*=6.9, 1.6 Hz), 7.64-7.58 (AA'BB', 2H, arom. H), 7.56-7.49 (AA'BB', 2H, arom. H), 7.44-7.38 (AA'BB', 2H, arom. H), 5.65 (s, 2H, CH₂).

Example 47

Preparation Of 5-(4-Bromobenzyl)-2-(2-pyridyl)-5*H*-imidazo[4,5-*c*]pyridine (GPJN-58)

A mixture of the 3,4-diaminopyridine (1.00 g), picolinic acid (1 equivalent) and polyphosphoric acid (25 g) was heated at 190°C for 3 h with stirring. Then the mixture was cooled to ambient temperature and poured into ice/water. The resulting mixture was made alkaline by addition of solid NaOH and the resulting precipitate was collected by filtration and dried. The crude product was recrystallized from a mixture of water (50 mL) and ethanol (7 mL) to give 55% of 2-(2-pyridyl)-1(3)*H*-imidazo[4,5-*c*]pyridine as an off-white powder.

2-(2-Pyridyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.327 g) was dissolved in dry DMF (10 mL) and the resulting solution was cooled to 0°C. Aqueous 33% sodium hydroxide (1.5 equivalents) was added and the mixture was stirred for 15 min. Then 4-bromobenzyl bromide (1.2 equivalents) was added portionwise and the resulting mixture was stirred for 24 h at room temperature. Finally, water (80 mL) was added, the precipitate was collected by filtration and dried to give the crude product.

Recrystallized from a mixture of ethyl acetate (75 mL) and ethanol (10 mL); pale brown crystals; mp: 256-258°C; yield: 43%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.21 (d, 1H, H4, *J*=1.4 Hz), 8.68 (ddd, 1H, pyridine-H6), 8.40 (ddd, 1H, pyridine-H), 8.20 (dd, 1H, H6, *J*=6.8,

1.4 Hz), 7.89 (ddd, H, pyridine-H), 7.79 (d, 1H, H7, J=6.8 Hz), 7.65-7.58 (AA'BB', 2H, arom. H), 7.45-7.37 (m, 3H, arom. H), 5.68 (s, 2H, CH₂).

Example 48

5 Preparation Of 5-(4-Bromobenzyl)-2-(3-pyridyl)-5H-imidazo[4,5-c]pyridine (GPJN-57)

A mixture of the 3,4-diaminopyridine (1.00 g), nicotinic acid (1 equivalent) and polyphosphoric acid (25 g) was heated at 190°C for 3 h with stirring. Then the mixture was cooled to ambient temperature and poured into ice/water. The resulting mixture was made
10 alkaline by addition of solid NaOH and the resulting solution was evaporated. The residue was extracted twice with ethyl acetate (2 x 200 mL) and the combined organic phases were dried (Na₂SO₄) and evaporated. The crude product, thus obtained, was recrystallized from a mixture of ethyl acetate (50 mL) and ethanol (13 mL) to give 34% of 2-(3-pyridyl)-1(3)H-imidazo[4,5-c]pyridine as an off-white powder.

15

2-(3-Pyridyl)-1(3)H-imidazo[4,5-c]pyridine (0.327 g) was dissolved in dry DMF (10 mL) and the resulting solution was cooled to 0°C. Aqueous 33% sodium hydroxide (1.5 equivalents) was added and the mixture was stirred for 15 min. Then, 4-bromobenzyl bromide (1.2 equivalents) was added portionwise and the resulting mixture was stirred for 24 h at room
20 temperature. Finally, water (80 mL) was added, the precipitate was collected by filtration and dried to give the crude product.

Recrystallized from a mixture of diisopropyl ether (10 mL), ethyl acetate (75 mL) and ethanol (20 mL); pale yellow powder; mp: 270-272°C; yield: 40%; ¹H NMR (200 MHz, DMSO-d₆) δ
25 9.49 (m, 1H, pyridine-H2), 9.18 (d, 1H, H4, J=1.5 Hz), 8.65-8.60 (m, 2H, arom. H), 8.21 (dd, 1H, H6, J=6.8, 1.5 Hz), 7.79 (d, 1H, H7, J=6.8 Hz), 7.65-7.58 (AA'BB', 2H, arom. H), 7.54-7.38 (m, 3H, arom. H), 5.66 (s, 2H, CH₂).

Example 49

30 Preparation Of 5-(4-Bromobenzyl)-2-(4-pyridyl)-5H-imidazo[4,5-c]pyridine (GPJN-49)

A mixture of the 3,4-diaminopyridine (1.00 g), isonicotinic acid (1 equivalent) and polyphosphoric acid (25 g) was heated at 190°C for 3 h with stirring. Then the mixture was cooled to ambient temperature and poured into ice/water. The resulting mixture was made

alkaline by addition of solid NaOH and the resulting precipitate was collected by filtration and dried. The crude product was recrystallized from water (55 mL) to give 84% of 2-(4-pyridyl)-1(3)*H*-imidazo[4,5-*c*]pyridine as a pale orange powder.

- 5 2-(4-Pyridyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.327 g) was dissolved in dry DMF (11 mL) and the resulting solution was cooled to 0°C. Aqueous 33% sodium hydroxide (1.5 equivalents) was added and the mixture was stirred for 15 min. Then 4-bromobenzyl bromide (1.2 equivalents) was added portionwise and the resulting mixture was stirred for 24 h at room temperature. Finally, water (80 mL) was added, the precipitate was collected by filtration and
10 dried to give the crude product.

Recrystallized from a mixture of diisopropyl ether (10 mL) and ethyl acetate (75 mL); pale brown powder; mp: 190-194°C (degr.); yield: 40%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.25 (d, 1H, H4, *J*=1.4 Hz), 8.70-8.67 (m, 2H, pyridine-H2/6), 8.25-8.20 (m, 3H, arom. H), 7.83 (d, 1H, H7, *J*=6.8 Hz), 7.64-7.58 (AA'BB', 2H, arom. H), 7.45-7.39 (AA'BB', 2H, arom. H),
15 5.68 (s, 2H, CH₂).

Example 50

Preparation Of 5-(4-Bromobenzyl)-2-(2-thienyl)-5*H*-imidazo[4,5-*c*]pyridine (GPN-53)

20

A mixture of the 3,4-diaminopyridine (1.00 g), thiophene-2-carboxylic acid (1 equivalent) and polyphosphoric acid (25 g) was heated at 190°C for 3 h with stirring. Then the mixture was cooled to ambient temperature and poured into ice/water. The resulting mixture was neutralized by addition of solid NaOH and the resulting precipitate was collected by filtration
25 and dried. The crude product was recrystallized from a mixture of water (50 mL) and ethanol (25 mL) to give 30% of 2-(2-thienyl)-1(3)*H*-imidazo[4,5-*c*]pyridine as pale yellow crystals.

2-(2-Thienyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.335 g) was dissolved in dry DMF (10 mL) and the resulting solution was cooled to 0°C. Aqueous 33% sodium hydroxide (1.5 equivalents)
30 was added and the mixture was stirred for 15 min. Then 4-bromobenzyl bromide (1.2 equivalents) was added portionwise and the resulting mixture was stirred for 24 h at room temperature. Finally, water (80 mL) was added, the precipitate was collected by filtration and dried to give the crude product.

Recrystallized from ethyl acetate (70 mL); pale yellow powder; mp: 230-231°C; yield: 24%;
¹H NMR (200 MHz, DMSO-d₆) δ 9.01 (d, 1H, H4, J=1.5 Hz), 8.16 (dd, 1H, H6, J=6.8, 1.5 Hz), 7.81 (dd, 1H, thiophene-H, J=3.6, 1.4 Hz), 7.67 (d, 1H, H7, J=6.8 Hz), 7.64-7.57 (m, 3H, arom. H), 7.43-7.37 (AA'BB', 2H, arom. H), 5.63 (s, 2H, CH₂).

5
Example 51

Preparation Of 2-Benzyl-5-(4-bromobenzyl)-5H-imidazo[4,5-c]pyridine (GPJN-67)

10 A mixture of the 3,4-diaminopyridine (1.00 g), phenylacetic acid (1 equivalent) and polyphosphoric acid (25 g) was heated at 120°C for 1 h and then at 150°C for 12 h with stirring. Then the mixture was cooled to ambient temperature and poured into ice/water. The resulting mixture was made alkaline by addition of solid NaOH and the resulting precipitate was collected by filtration and dried. The crude product was recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (76 mL) to give 57% of 2-benzyl-1(3)*H*-
15 imidazo[4,5-c]pyridine as a colorless powder.

2-Benzyl-1(3)*H*-imidazo[4,5-c]pyridine (0.500 g) was dissolved in dry DMF (5 mL) and the resulting solution was cooled to 0°C. Aqueous 33% sodium hydroxide (1.5 equivalents) was added and the mixture was stirred for 15 min. Then 4-bromobenzyl bromide (1.2 equivalents)
20 was added portionwise and the resulting mixture was stirred for 24 h at room temperature. Finally, water (80 mL) was added, the precipitate was collected by filtration and dried to give the crude product.

Recrystallized from a mixture of ethyl acetate (50 mL) and ethanol (6.5 mL); pale yellow
25 powder; mp: 232-233°C; yield: 46%; ¹H NMR (200 MHz, DMSO-d₆) δ 8.94 (d, 1H, H4, J=1.4 Hz), 8.10 (dd, 1H, H6, J=6.8, 1.4 Hz), 7.61-7.39 (m, 3H, arom. H), 7.38-7.10 (m, 7H, arom. H), 5.65 (s, 2H, 5-CH₂), 4.17 (s, 2H, 2-CH₂).

Example 52

30 Preparation Of 5-(4-Bromobenzyl)-2-(1-naphthyl)-5H-imidazo[4,5-c]pyridine (GPJN-62)

A mixture of the 3,4-diaminopyridine (1.00 g), 1-naphthoic acid (1 equivalent) and polyphosphoric acid (25 g) was heated at 190°C for 3 hours with stirring. Then the mixture

was cooled to ambient temperature and poured into ice/water. The resulting mixture was made alkaline by addition of solid NaOH and the resulting precipitate was collected by filtration and dried. The crude product was recrystallized from a mixture of water (100 mL) and ethanol (130 mL) to give 47% of 2-(1-naphthyl)-1(3)*H*-imidazo[4,5-*c*]pyridine as an off-white powder.

2-(1-Naphthyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.409 g) was dissolved in dry DMF (10 mL) and the resulting solution was cooled to 0°C. Aqueous 33% sodium hydroxide (1.5 equivalents) was added and the mixture was stirred for 15 min. Then 4-bromobenzyl bromide (1.2 equivalents) was added portionwise and the resulting mixture was stirred for 24 h at room temperature. Finally, water (80 mL) was added, the precipitate was collected by filtration and dried to give the crude product.

Recrystallized from a mixture of diisopropyl ether (10 mL), ethyl acetate (50 mL) and ethanol (5 mL); pale yellow powder; mp: 210-213°C (degr.); yield: 22%; ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.73 (m, 1H, arom. H), 9.22 (d, 1H, H4, *J*=1.6 Hz), 8.52 (dd, 1H, arom. H, *J*=7.2, 1.4 Hz), 8.23 (dd, 1H, H6, *J*=6.8, 1.6 Hz), 8.03-7.95 (m, 2H, arom. H), 7.83 (d, 1H, H7, *J*=6.8 Hz), 7.65-7.41 (m, 7H, arom. H), 5.68 (s, 2H, CH₂).

Example 53

Preparation Of 5-(4-Bromobenzyl)-2-(2-naphthyl)-5*H*-imidazo[4,5-*c*]pyridine (GPJN-63)

A mixture of the 3,4-diaminopyridine (1.00 g), 2-naphthoic acid (1 equivalent) and polyphosphoric acid (25 g) was heated at 190°C for 3 hours with stirring. Then the mixture was cooled to ambient temperature and poured into ice/water. The resulting mixture was made alkaline by addition of solid NaOH and the resulting precipitate was collected by filtration and dried. The crude product was recrystallized from a mixture of water (100 mL) and ethanol (400 mL) to give 28% of 2-(2-naphthyl)-1(3)*H*-imidazo[4,5-*c*]pyridine as an off-white powder.

2-(2-Naphthyl)-1(3)*H*-imidazo[4,5-*c*]pyridine (0.409 g) was dissolved in dry DMF (10 mL) and the resulting solution was cooled to 0°C. Aqueous 33% sodium hydroxide (1.5 equivalents) was added and the mixture was stirred for 15 min. Then 4-bromobenzyl bromide (1.2 equivalents) was added portionwise and the resulting mixture was stirred for 24 h at room

temperature. Finally, water (80 mL) was added, the precipitate was collected by filtration and dried to give the crude product.

Recrystallized from a mixture of diisopropyl ether (20 mL) and ethyl acetate (60 mL); pale orange powder; mp: 133-138°C (degr.); yield: 52%; ¹H NMR (200 MHz, DMSO-d₆) δ 9.13 (d, 1H, H4, J=1.4 Hz), 8.93 (br s, 1H, arom. H), 8.51 (dd, 1H, arom. H, J=8.6, 1.6 Hz), 8.19 (dd, 1H, H6, J=6.7, 1.4 Hz), 8.10-7.90 (m, 3H, arom. H), 7.76 (d, 1H, H7, J=6.7 Hz), 7.65-7.50 (m, 4H, arom. H), 7.52-7.39 (AA'BB', 2H, arom. H), 5.67 (s, 2H, CH₂).

10

PART B

Example 54

15 Anti-BVDV (strain PE515) activity in MDBK cells

Compound	example	EC ₅₀ (µg/ml)	CC ₅₀ (µg/ml)	SI
GPJN-1	4	0.240	> 83.3	>345
GPJN-2	7	>100	>100	1
GPJN-3	5	0.060	60	1003
GPJN-4	6	0.040	46	1144
GPJN-7	9	0.042	22	525
GPJN-8	10	0.086	51	592
GPJN-9	11	0.049		
GPJN-9 xHCl	25	0.016		
GPJN-11	12	0.032	36	1135
GPJN-12	13	0.059	56	949
GPJN-13	14	0.043	45	1058
GPJN-14	8	0.070	40	573
GPJN-15	17	0.009	29	3079
GPJN-16	21	0.246	8,1	33
GPJN-17	18	0.097	50	517
GPJN-18	19	0.019	55	2933
GPJN-19	20	0.013	40	3012
GPJN-20	15	0.165	28	169
GPJN-21	16	0.022	22	1020
GPJN-22	22	0.029	13	450
GPJN-23	23	0.014	46	3230
GPJN-24	24	0.040	21	519

GPJN-25	26	0.009	36	4138
GPJN-26	27	0.041	>100	>2439
GPJN-27	28	0.945	>46	>48
GPJN-28	29	0.325	>75	>230
GPJN-29	30	5.330	>100	>18
GPJN-30	31	1.130	>50	>44
GPJN-31	32	0.455	>100	>222
GPJN-32	35	0.027	20	741
GPJN-33	36	0.200	70	350
GPJN-34	33	0.865	>100	>116
GPJN-35	34	0.365	>100	>273
GPJN-36	37	0.019	24	1297
GPJN-37	38	0.161	22	137
GPJN-38	39	0.235	60	213
GPJN-39	40	0.245	>100	>408
GPJN-40	41	0.250	>100	>400
GPJN-41	42	0.580	>100	>172
GPJN-48	43	0.351	>100	>285
GPJN-49	49	0.180	62	344
GPJN-50		0.021	>100	4760
GPJN-53	50	0.033	66	2028
GPJN-54	44	0.100	35	349
GPJN-55	45	0.060	>100	>1666
GPJN-56	46	2.205	>100	>45
GPJN-57	48	2.005	>100	>50
GPJN-58	47	0.052	8,1	156
GPJN-60		0.015	>77	5133
GPJN-62	52	0.120	9,4	78
GPJN-63	53	0.0042	4.3	1023
GPJN-64		0.026	>100	3846
GPJN-66		0.01	>100	10.000
GPJN-67	51	>100	>100	>100
GPJN-68		0.026	17	653
GPJN-73		0.017	>100	6882
GPJN-75		0.018	31.7	1761
GPJN-79		0.083	>100	1204
GPJN-80		0.18	>100	555
GPRTI-8	3	0.137	>79	>576
VP32947**		0.003	47	>16785

*** Baginsky et al., Proc Natl Acad Sci U S A 2000 Jul 5;97(14):7981-6*

EC₅₀: effective concentration required to reduce virus induced cytopathic effect in MDBK cells by 50%.

IC₅₀: inhibitory concentration required to reduce the growth of exponentially growing MDBK cells by 50%

SI: IC₅₀/EC₅₀.

5 *Data are mean values for 2-5 independent determinations*

Example 55

Anti-coxsackie B3 activity in Vero cells

5

Compound	example	EC ₅₀ (µg/ml)	TC ₅₀ (µg/ml)	SI
GPJN-5		6.0	>100	16.6
GPJN-32	35	6.5	69	15.4
GPJN-40	41	8.95	>100	11.2
GPJN-50		8.47	>100	11.8
GPJN-60		6.1	>100	16.4
GPJN-64		12	>42	3.5
GPRTI-8	3	12.2	>100	8.48

EC₅₀: effective concentration required to reduce virus (CBV-3 Nancy strain)-induced cytopathic effect in Vero cells by 50%.

TC₅₀: effective concentration required to reduce the metabolism of confluent Vero cells by 50% as determined by the MTS method.


SI: IC₅₀/EC₅₀

Data are mean values for two or more independent determinations

10

CLAIMS

5 1. A compound according to formula I



or a pharmaceutically acceptable salt thereof, wherein

10

R^1 is selected from hydrogen; phenyl substituted with 0-3 R^6 ; (benzoannellated) 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^6 ; 1-naphthyl substituted with 0-3 R^6 ; 2-naphthyl substituted with 0-3 R^6 ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl with the proviso that the double bond cannot be adjacent to a nitrogen.

15

Y is selected from the group $-(CH_2)_{0-5}$; O; S; NR^{11} ; $-CH(CH_3)-$; $-OCH_2-$; $-CH_2O-$; $-OCH_2-CH_2-$; $-CH_2-CH_2O-$; $-CH_2-O-CH_2-$; $-SCH_2-$; $-CH_2S-$; $-SCH_2-CH_2-$; $-CH_2-CH_2S-$; $-CH_2-S-CH_2-$; $-NR^{11}-CH_2-$; $-CH_2-NR^{11}-$; $-NR^{11}-CH_2-CH_2-$; $-CH_2-CH_2-NR^{11}-$; $-CH_2-NR^{11}-CH_2-$; $-C(CH_3)_2-$; (cis or trans) $-CH=CH-$; (cis or trans) $-CH_2-CH=CH-$; (cis or trans) $-CH=CH-CH_2-$.

20

R^2 , R^4 and R^5 are independently selected from hydrogen; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; NR^7R^8 ; OCF_3 ; CF_3 ; $C(=O)R^9$; phenyl; phenoxy; benzyl; hydroxymethyl.

25

X is selected from the group $-CH_2-$; $-CH(CH_3)-$; $-CH_2-CH_2-$; $-CH_2-CH_2-CH_2-$; $-CH_2-CH_2-CH_2-CH_2-$; $-OCH_2-CH_2-$; $-SCH_2-CH_2-$; $-NR^{10}-CH_2-CH_2-$; C_{3-7} cycloalkylidene; $-C(CH_3)_2-$; $-CH_2-CH(CH_3)-CH_2-$; $-CH(CH_3)-CH_2-CH_2-$; $-CH_2-CH_2-CH(CH_3)-$; $-CH=CH-CH_2-$.

R^3 is selected from phenyl substituted with 0-3 R^{17} ; (benzoannellated) 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^{17} ; 1-naphthyl substituted with 0-3 R^{17} ; 2-naphthyl substituted with 0-3 R^{17} ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl with the proviso that the double bond cannot be adjacent to a nitrogen.

R^6 and R^{17} are independently selected from the group H; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; $NR^{13}R^{14}$; OCF_3 ; CF_3 ; $C(=O)R^{18}$; phenyl; phenoxy; benzyl; hydroxymethyl.

R^7 and R^8 are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

alternatively, R^7 and R^8 , together with the nitrogen to which they are attached, combine to form a 5-6 membered ring containing 0-1 O or N atoms.

R^9 and R^{18} are independently selected from H; OH; straight or branched C_{1-6} alkyl; straight or branched C_{1-6} alkoxy; $NR^{15}R^{16}$; phenyl.


R^{10} and R^{11} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

R^{12} is selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

R^{13} and R^{14} are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

R^{15} and R^{16} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

2. A compound according to formula II



or a pharmaceutically acceptable salt thereof, wherein

5

R^1 is selected from phenyl substituted with 0-3 R^6 ; (benzoannellated) 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^6 ; 1-naphthyl substituted with 0-3 R^6 ; 2-naphthyl substituted with 0-3 R^6 ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl.

10

R^2 , R^4 and R^5 are independently selected from hydrogen; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; NR^7R^8 ; OCF_3 ; CF_3 ; $C(=O)R^9$; phenyl; phenoxy; benzyl; hydroxymethyl.

15

X is selected from the group $-CH_2-$; $-CH(CH_3)-$; $-CH_2-CH_2-$; $-CH_2-CH_2-CH_2-$; $-CH_2-CH_2-CH_2-CH_2-$; $-OCH_2-CH_2-$; $-SCH_2-CH_2-$; $-NR^{10}-CH_2-CH_2-$; C_{3-7} cycloalkylidene; $-C(CH_3)_2-$; $-CH_2-CH(CH_3)-CH_2-$; $-CH(CH_3)-CH_2-CH_2-$; $-CH_2-CH_2-CH(CH_3)-$; $-CH=CH-CH_2-$.

20

R^3 is selected from phenyl substituted with 0-3 R^{17} ; (benzoannellated) 5 or 6 membered aromatic heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^{17} ; 1-naphthyl substituted with 0-3 R^{17} ; 2-naphthyl substituted with 0-3 R^{17} ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl with the proviso that the double bond cannot be adjacent to a nitrogen.

25

R^6 and R^{17} are independently selected from the group H; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; $NR^{13}R^{14}$; OCF_3 ; CF_3 ; $C(=O)R^{18}$; phenyl; phenoxy; benzyl; hydroxymethyl.

R^7 and R^8 are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

alternatively, R^7 and R^8 , together with the nitrogen to which they are attached, combine to form a 5-6 membered ring containing 0-1 O or N atoms.

R^9 and R^{18} are independently selected from H; OH; straight or branched C_{1-6} alkyl; straight or branched C_{1-6} alkoxy; $NR^{15}R^{16}$; phenyl.

R^{10} is selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

R^{12} is selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

R^{13} and R^{14} are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

R^{15} and R^{16} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

3. A compound according to claim 2, characterised in that

R^1 is selected from phenyl substituted with 0-3 R^6 ; (benzoannellated) 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^6 ; 1-naphthyl substituted with 0-3 R^6 ; 2-naphthyl substituted with 0-3 R^6 ; C_{3-7} cycloalkyl; C_{3-7} cycloalkenyl.

R^2 , R^4 and R^5 are independently selected from hydrogen; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; NR^7R^8 ; OCF_3 ; CF_3 ; $C(=O)R^9$; phenyl; phenoxy; benzyl; hydroxymethyl.

X is selected from the group $-CH_2-$; $-CH(CH_3)-$; $-CH_2-CH_2-CH_2-$; $-OCH_2-CH_2-$; $-CH=CH-CH_2-$.

R^3 is selected from phenyl substituted with 0-3 R^{17} ; (benzoannellated) 5 or 6 membered aromatic heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^{17} ; 1-naphthyl substituted with 0-3 R^{17} ; 2-naphthyl substituted with 0-3 R^{17} ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl with the proviso that the double bond cannot be adjacent to a nitrogen.

R^6 and R^{17} are independently selected from the group H; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; $NR^{13}R^{14}$; OCF_3 ; CF_3 ; $C(=O)R^{18}$; phenyl; phenoxy; benzyl; hydroxymethyl.

10

R^7 and R^8 are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

15

alternatively, R^7 and R^8 , together with the nitrogen to which they are attached, combine to form a 5-6 membered ring containing 0-1 O or N atoms.

R^9 and R^{18} are independently selected from H; OH; straight or branched C_{1-6} alkyl; straight or branched C_{1-6} alkoxy; $NR^{15}R^{16}$; phenyl.

20

R^{12} is selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

R^{13} and R^{14} are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

25

R^{15} and R^{16} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

4. A compound according to claim 2, characterised in that

30

R^1 is selected from phenyl substituted with 0-3 R^6 ; (benzoannellated) 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^6 ; 1-naphthyl substituted with 0-3 R^6 ; 2-naphthyl substituted with 0-3 R^6 ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl.

R^2 , R^4 and R^5 are hydrogen.

X is selected from the group $-\text{CH}_2-$; $-\text{CH}(\text{CH}_3)-$; $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$; $-\text{OCH}_2-\text{CH}_2-$; $-\text{CH}=\text{CH}-\text{CH}_2-$.

5

R^3 is selected from phenyl substituted with 0-3 R^{17} ; (benzoannellated) 5 or 6 membered aromatic heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^{17} ; 1-naphthyl substituted with 0-3 R^{17} ; 2-naphthyl substituted with 0-3 R^{17} ; C_{3-7} cycloalkyl; C_{5-7} cycloalkenyl with the proviso that the double bond cannot be adjacent to a nitrogen.

10

R^6 and R^{17} are independently selected from the group H; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; $\text{NR}^{13}\text{R}^{14}$; OCF_3 ; CF_3 ; $\text{C}(=\text{O})\text{R}^9$; phenyl; phenoxy; benzyl; hydroxymethyl.

15

R^9 is selected from H; OH; straight or branched C_{1-6} alkyl; straight or branched C_{1-6} alkoxy; $\text{NR}^{15}\text{R}^{16}$; phenyl.

R^{13} and R^{14} are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $\text{C}(=\text{O})\text{R}^{12}$.

20

R^{15} and R^{16} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

25

5. A compound according to claim 2, characterised in that

R^1 is selected from phenyl substituted with 0-3 R^6 ; (benzoannellated) 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^6 ; 1-naphthyl substituted with 0-3 R^6 ; 2-naphthyl substituted with 0-3 R^6 .

30

R^2 , R^4 and R^5 are hydrogen.

X is selected from $-\text{CH}_2-$; $-\text{CH}(\text{CH}_3)-$; $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$; $-\text{OCH}_2-\text{CH}_2-$; $-\text{CH}=\text{CH}-\text{CH}_2-$.

R^3 is selected from phenyl substituted with 0-3 R^{17} ; (benzoannellated) 5 or 6 membered aromatic heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^{17} ; 1-naphthyl substituted with 0-3 R^{17} ; 2-naphthyl substituted with 0-3 R^{17} .

R^6 and R^{17} are independently selected from the group H; straight or branched C_{1-6} alkoxy; straight or branched C_{1-6} alkyl; F; Cl; Br; I; OH; CN; NO_2 ; $NR^{13}R^{14}$; OCF_3 ; CF_3 ; $C(=O)R^9$; phenyl; phenoxy; benzyl; hydroxymethyl.

R^9 is selected from H; OH; straight or branched C_{1-6} alkyl; straight or branched C_{1-6} alkoxy; $NR^{15}R^{16}$; phenyl.

R^{13} and R^{14} are independently selected from H; straight or branched C_{1-6} alkyl; phenyl; $C(=O)R^{12}$.

R^{15} and R^{16} are independently selected from the group H; C_{1-6} straight or branched alkyl; phenyl.

6. A compound according to claim 2, characterised in that

R^1 is selected from phenyl substituted with 0-3 R^6 ; 5 or 6 membered heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^6 ; 1-naphthyl substituted with 0-3 R^6 ; 2-naphthyl substituted with 0-3 R^6 .

R^2 , R^4 and R^5 are hydrogen.

X is selected from $-CH_2-$; $-CH(CH_3)-$; $-CH_2-CH_2-CH_2-$; $-OCH_2-CH_2-$; $-CH=CH-CH_2-$.

R^3 is selected from phenyl substituted with 0-3 R^{17} ; 5 or 6 membered aromatic heterocyclic ring containing 1-3 heteroatoms selected from the group O, N, and S, substituted with 0-2 R^{17} ; 1-naphthyl substituted with 0-3 R^{17} ; 2-naphthyl substituted with 0-3 R^{17} .

R⁶ and R¹⁷ are independently selected from hydrogen; straight or branched C₁₋₆ alkoxy; straight or branched C₁₋₆ alkyl; F; Cl; Br; I; OH; CN; NO₂; NR¹³R¹⁴; OCF₃; CF₃; C(=O)R⁹; phenyl; phenoxy; benzyl; hydroxymethyl.

5 R⁹ is selected from H; OH; straight or branched C₁₋₆ alkyl; straight or branched C₁₋₆ alkoxy; NR¹⁵R¹⁶; phenyl.

R¹³ and R¹⁴ are independently selected from H; straight or branched C₁₋₆ alkyl; phenyl; C(=O)R¹².

10 R¹⁵ and R¹⁶ are independently selected from the group H; C₁₋₆ straight or branched alkyl; phenyl.

7. A compound according to claim 1 or claim 2 selected of the group of

- 15 5-(2,6-Difluorobenzyl)-2-(2,6-difluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-Benzyl-2-(2,6-difluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(2,6-Difluorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-Benzyl-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
2-(2,6-Difluorophenyl)-5-phenethyl-5*H*-imidazo[4,5-*c*]pyridine;
20 2-Phenyl-5-(3-phenyl-propyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(2-Chlorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(3-Chlorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Chlorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(2-Methoxybenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
25 5-(3-Methoxybenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Methoxybenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Methylbenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(3-Fluorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Fluorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
30 5-(4-Bromobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
4-(2-Phenyl-5*H*-imidazo[4,5-*c*]pyridin-5-ylmethyl)-benzonitrile;
5-(4-Trifluoromethyl-benzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Chlorobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine hydrochloride;
5-(5-Chloro-2-thienylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;

- 5-(2-Naphthylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
2-Phenyl-5-(4-phenyl-butyl)-5*H*-imidazo[4,5-*c*]pyridine;
2-Phenyl-5-(4-phenyl-benzyl)-5*H*-imidazo[4,5-*c*]pyridine;
(*R/S*)-2-Phenyl-5-(1-phenyl-ethyl)-5*H*-imidazo[4,5-*c*]pyridine;
5 5-(1-Naphthylmethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(2,4-Difluorobenzyl)-2-(2,6-difluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(2-chlorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(3-chlorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(4-chlorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
10 5-(4-Bromobenzyl)-2-(2-pyridyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(2-thienyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(1-naphthyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(2-naphthyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Iodobenzyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
15 5-(4-Bromobenzyl)-2-(3-fluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(3-methylphenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(3-bromophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(4-Bromobenzyl)-2-(3-methoxyphenyl)-5*H*-imidazo[4,5-*c*]pyridine.
5-(4-Chlorobenzyl)-2-(3-bromophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
20 5-(4-Chlorobenzyl)-2-(3-chlorophenyl)-5*H*-imidazo[4,5-*c*]pyridine;
5-(2-Phenoxy-ethyl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine;
5-(3-Phenyl-prop-2-en-1-yl)-2-phenyl-5*H*-imidazo[4,5-*c*]pyridine and
5-(4-Iodobenzyl)-2-(3-bromophenyl)-5*H*-imidazo[4,5-*c*]pyridine.
25 8. A compound according to any of claims 1 to 9 for use as a medicine.
9. A compound according to any of claims 1 to 9 for use as an antiviral agent.
10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as
30 active ingredient, a therapeutically effective amount of a compound according to any of
claims 1 to 9.


11. Use of a compound according to any of the claims 1 to 9 or a pharmaceutical composition according to claim 10 for the manufacture of a medicament in the treatment or prevention of viral infection
- 5 12. Use of a compound according to any of the claims 1 to 9 or a pharmaceutical composition according to claim 10 for the manufacture of a medicament in the treatment or prevention of a viral infection with a virus belonging to the family of the Flaviviridae.
- 10 13. Use of a compound according to any of the claims 1 to 9 or a pharmaceutical composition according to claim 10 for the manufacture of a medicament in the treatment or prevention of a viral infection with hepatitis-C-virus.
- 15 14. Use of a compound according to any of the claims 1 to 9 or a pharmaceutical composition according to claim 10 for the manufacture of a medicament in the treatment or prevention of a viral infection with a viruses belonging to the family of the Picornaviridae.
- 20 15. Use of a compound according to any of the claims 1 to 9 or a pharmaceutical composition according to claim 10 for the manufacture of a medicament in the treatment or prevention of a viral infection with a Cocksackie virus.

ABSTRACT


5

Viral inhibitors

The present inventions relates to a pharmaceutical composition for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine derivative having the general formula (I) or (II)



I



II

15

The invention also relates to processes for the preparation of the compounds according to the invention having above mentioned general formula and their use as a medicine to treat or prevent viral infection.

20

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.